Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial
Journal of Gastroenterology and Hepatology Nov 02, 2019
Sarkeshikian SS, et al. – Researchers performed a randomized, controlled trial to assess the effect of atorvastatin on eradication of Helicobacter pylori. The control and intervention arms each consisted of 110 patients with H. pylori infection. Patients in the control group received a 14-day regimen of amoxicillin, clarithromycin, bismuth, and esomeprazole; those in intervention group received 40 mg of atorvastatin daily plus the antibiotic regimen for 14 weeks. The investigators examined study results 1 month later using H. pylori stool antigen test, and collected data using checklist and analyzed using chi-squared and Fisher’s exact tests with SPSS version 18. In the intervention and control groups, H. pylori eradication rates were 78.18% and 65.45%, respectively, with a notable variation in terms of non-ulcer dyspepsia among the groups. However, there was no important variation in age, sex, and BMI across the two groups. According to findings, with respect to the eradication of H. pylori, adding atorvastatin to the four-drug regimen of omeprazole, clarithromycin, bismuth, and amoxicillin is efficient. Moreover, adding atorvastatin to H. pylorieradication therapy may be more efficient in individuals with non-ulcer dyspepsia.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries